242 related articles for article (PubMed ID: 34014535)
1. The Intricate Metabolism of Pancreatic Cancers.
Camelo F; Le A
Adv Exp Med Biol; 2021; 1311():77-88. PubMed ID: 34014535
[TBL] [Abstract][Full Text] [Related]
2. The Intricate Metabolism of Pancreatic Cancers.
Camelo F; Le A
Adv Exp Med Biol; 2018; 1063():73-81. PubMed ID: 29946776
[TBL] [Abstract][Full Text] [Related]
3. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
4. Ferroptosis: New Strategies and Ideas for the Treatment of Pancreatic Ductal Adenocarcinoma.
Yang C; Dong Q; Bao H; Ge Y; Xu Z; Li J; Jiang X; Xu Y; Zhong X
Front Biosci (Landmark Ed); 2024 Jan; 29(1):45. PubMed ID: 38287825
[TBL] [Abstract][Full Text] [Related]
5. Loss of heterozygosity for Kras
Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P
Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996
[TBL] [Abstract][Full Text] [Related]
6. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
Sun H; Zhang B; Li H
Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692
[TBL] [Abstract][Full Text] [Related]
7. The molecular genetics of pancreatic ductal carcinoma.
Sohn TA
Minerva Chir; 2002 Oct; 57(5):561-74. PubMed ID: 12370658
[TBL] [Abstract][Full Text] [Related]
8. The molecular genetics of pancreatic ductal carcinoma: a review.
Sohn TA; Yeo CJ
Surg Oncol; 2000 Nov; 9(3):95-101. PubMed ID: 11356337
[TBL] [Abstract][Full Text] [Related]
9. Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression.
McCubrey JA; Yang LV; Abrams SL; Steelman LS; Follo MY; Cocco L; Ratti S; Martelli AM; Augello G; Cervello M
Cells; 2022 Jul; 11(14):. PubMed ID: 35883598
[TBL] [Abstract][Full Text] [Related]
10. [A Review of Metabolic Stress and Development of Pancreatic Cancer].
Li JT; Lei MZ; Lei QY; Yin M
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Jan; 52(1):5-10. PubMed ID: 33474881
[TBL] [Abstract][Full Text] [Related]
11. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential.
Knudsen ES; Balaji U; Freinkman E; McCue P; Witkiewicz AK
Oncotarget; 2016 Nov; 7(48):78396-78411. PubMed ID: 27623078
[TBL] [Abstract][Full Text] [Related]
12. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
13. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
14. [Epithelial-stromal interactions in pancreatic adenocarcinoma: the role of stroma in disease progression].
Kuznetsova AV; Popova OP; Astakhov DA; Ivanov YV; Panchenkov DN; Ivanov AA
Arkh Patol; 2022; 84(5):65-70. PubMed ID: 36178225
[TBL] [Abstract][Full Text] [Related]
15. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes.
Immervoll H; Hoem D; Kugarajh K; Steine SJ; Molven A
Virchows Arch; 2006 Jun; 448(6):788-96. PubMed ID: 16598499
[TBL] [Abstract][Full Text] [Related]
16. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
Inagawa Y; Yamada K; Yugawa T; Ohno S; Hiraoka N; Esaki M; Shibata T; Aoki K; Saya H; Kiyono T
Carcinogenesis; 2014 Aug; 35(8):1840-6. PubMed ID: 24858378
[TBL] [Abstract][Full Text] [Related]
17. Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma.
Ng CF; Glaspy J; Placencio-Hickok VR; Thomassian S; Gong J; Osipov A; Hendifar AE; Moshayedi N
J Natl Compr Canc Netw; 2022 Oct; 20(10):1076-1079. PubMed ID: 36240849
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
19. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma.
Tu B; Yao J; Ferri-Borgogno S; Zhao J; Chen S; Wang Q; Yan L; Zhou X; Zhu C; Bang S; Chang Q; Bristow CA; Kang Y; Zheng H; Wang H; Fleming JB; Kim M; Heffernan TP; Draetta GF; Pan D; Maitra A; Yao W; Gupta S; Ying H
JCI Insight; 2019 Nov; 4(21):. PubMed ID: 31557131
[TBL] [Abstract][Full Text] [Related]
20. Carcinogenesis of Pancreatic Ductal Adenocarcinoma.
Storz P; Crawford HC
Gastroenterology; 2020 Jun; 158(8):2072-2081. PubMed ID: 32199881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
